TOP NEWS UPDATES

Pfizer, BioNTech not sure on vaccines’ effectiveness on new COVID variant ‘Omicron’

Washington [US]: The pharmaceutical companies Pfizer and BioNTech on Saturday issued a statement stating that they are not sure whether their vaccines would be able to help in the treatment of the new COVID-19 variant ‘Omicron’.The companies also promised to develop a new vaccine against the variant in about 100 days, Sputnik reported. This came after the World Health Organization (WHO) announced it identified a new COVID-19 strain, the B.1.1.529 that was initially found in southern Africa. WHO named the variant with the Greek letter ‘Omicron’.“In the event that vaccine-escape variant emerges, Pfizer and BioNTech expect to be able to develop and produce a tailor-made vaccine against that variant in approximately 100 days, subject to regulatory approval,” they added in the statement.As reported by Sputnik, Pfizer and BioNTech said they expect more data on Omicron within the next two weeks and noted the variant…

Corona Updates

Bharat Biotech’s Covaxin phase 3 data shows 77.8 pc efficacy against COVID-19, says Lancet

Hyderabad (Telangana) [India]: Hyderabad-based Bharat Biotech on Friday announced that the Lancet peer-review confirmed the efficacy analysis of Bharat Biotech’s Covaxin.As per phase-three clinical trials data, Covaxin demonstrates 77.8 per cent efficacy against symptomatic COVID-19. “COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2 per cent,” the official statement issued by Bharat Biotech said citing the study by the Lancet.“Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group,” said the company’s statement.Further, it said that Covaxin will be 93.4 per cent effective against severe symptomatic COVID-19.“Safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less…

TOP NEWS UPDATES

Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8% efficacy against COVID 19

Hyderabad-based Bharat Biotech on Saturday concluded a final analysis for its vaccine Covaxin efficacy from phase-3 clinical trial claiming it to be 77.8 per cent effective against COVID-19. It also added that Covaxin gives 65.2 per cent protection against the SARS-CoV-2, B.1.617.2 Delta variant. “Efficacy analysis demonstrates Covaxin to be 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group. Efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19,” the company said. As per the company, safety analysis demonstrates adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side effects and less than 0.5 per cent of subjects feeling serious adverse events. “Efficacy data demonstrates 63.6 per cent protection against asymptomatic COVID-19. Efficacy data demonstrates 65.2…